Differential modulation of PI3K /Akt/ mTOR activity by EGFR inhibitors: A rationale for co‐targeting EGFR and PI3K in cisplatin‐resistant HNSCC
Head & Neck · 2024-05 · 46 (5) · 1126-1135
DOI: 10.1002/hed.27718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2024-03. Verfasst von Jipei Liao und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Cisplatin, Head and Neck Neoplasms, Aminopyridines, Morpholines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NCI NIH HHS, National Institute of Dental and Craniofacial Research.
Abstract (Originalsprache)
Purpose
To find a new strategy to treat cisplatin‐resistant head and neck squamous cell carcinoma (HNSCC), we investigated the effects of EGFR inhibitors on the PI3K/Akt/mTOR pathway and determined the efficacy of EGFR inhibitors in combination with PI3K inhibitors to suppress cell proliferation in cisplatin‐resistant‐HNSCC.
Methods
The cisplatin‐resistant HNSCC cell lines were treated with four FDA approved EGFR inhibitors, which included Gefitinb or Erlotinib alone, or in combination with the pan‐PI3K inhibitor, BKM120. Phosphorylation and total protein levels of cells were assessed by Western blot analysis. Cell proliferation was examined by MTS assay. Apoptosis was analyzed by flow cytometry.
Results
Cisplatin‐resistant HNSCC cells were also resistant to EGFR inhibitors. However, a combination of EGFR inhibitors with PI3K inhibitor BKM120 dramatically improved the efficacy of EGFR inhibitors to inhibit cell proliferation and induce apoptosis. Furthermore, treatment with EGFR inhibitors differentially affected the phosphorylation of Akt and mTOR, which included partial inhibition, no inhibition, and induction. A combination of EGFR inhibitors and BKM120 completely blocked phosphorylation of EGFR, Akt, and S6K (an mTOR target).
Conclusion
Our data provided a rationale for EGFR inhibitors in combination with PI3K inhibitors to treat cisplatin‐resistant HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Hancai Dan
Förderung
- NIDCR NIH HHS
- NCI NIH HHS
- National Institute of Dental and Craniofacial Research
- National Cancer Institute
Zitieren
APA
Liao, J., Yang, Z., Azarbarzin, S., Cullen, K. J., & Dan, H. (2024). Differential modulation of PI3K /Akt/ mTOR activity by EGFR inhibitors: A rationale for co‐targeting EGFR and PI3K in cisplatin‐resistant HNSCC. Head & Neck, 46(5), 1126-1135. https://doi.org/10.1002/hed.27718
Vancouver
Liao J, Yang Z, Azarbarzin S, Cullen KJ, Dan H. Differential modulation of PI3K /Akt/ mTOR activity by EGFR inhibitors: A rationale for co‐targeting EGFR and PI3K in cisplatin‐resistant HNSCC. Head & Neck. 2024;46(5):1126-1135. doi:10.1002/hed.27718
BibTeX
@article{Liao2024,
author = {Liao, Jipei and Yang, Zejia and Azarbarzin, Shirin and Cullen, Kevin J and Dan, Hancai},
title = {Differential modulation of PI3K /Akt/ mTOR activity by EGFR inhibitors: A rationale for co‐targeting EGFR and PI3K in cisplatin‐resistant HNSCC},
journal = {Head & Neck},
year = {2024},
volume = {46},
number = {5},
pages = {1126--1135},
doi = {10.1002/hed.27718}
}
EUVIMED